Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor for prevention of thrombotic events in patients with history of MI
NCT01225562Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in myocardial infarction (MI) and stroke (3 arms), sponsored by AstraZeneca. Primary endpoints: Composite of Cardiovascular Death, Myocardial Infarction, or Stroke at 3 years and TIMI Major Bleeding at 3 years. Started Oct 2010; status: completed.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)stroke
Beyond the preview
Go deeper on NCT01225562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225562.